A sweeping review of randomized trial evidence found that left atrial appendage occlusion reduces non-procedural bleeding but did not lower mortality or all-cause major bleeding versus anticoagulation. The analysis also suggested a potential trade-off—higher ischemic stroke risk—compared with continued anticoagulant therapy. For clinicians and guideline committees, the mixed balance between bleeding and ischemic outcomes makes patient selection central, especially for populations where anticoagulation risk is otherwise manageable. The review reframes LAA occlusion as a procedure that can shift bleeding risk rather than eliminate the overall event burden, emphasizing the need to weigh ischemic versus hemorrhagic profiles in atrial fibrillation care.